Neoplasm by Site

In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Among the 6 patients with RET-fusion positive papil… (full text at CIViC)

Open in CIViC

Patients with RET-fusion positive non-small cell lung cancer were enrolled in this phase 1-2 trial of RET inhibitor selpercatinib. Among 105 consecutively enrolled patients who had previously received… (full text at CIViC)

PMID 32846060 · Drilon et al., 2020 · Open in CIViC

In this arm of the trial (NCT03157128), the intracranial objective response rate (iORR) was assessed in 80 patients with RET fusion-positive non-small cell lung cancer (NSCLC) treated with selpercatin… (full text at CIViC)

PMID 34088726 · Subbiah et al., 2021 · Open in CIViC

RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset. This study was a multi-center, open-label, phase II clinical trial to examine the safety and effi… (full text at CIViC)

PMID 27803005 · Lee et al., 2017 · Open in CIViC

We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged N… (full text at CIViC)

PMID 27825616 · Yoh et al., 2017 · Open in CIViC

In this multi-cohort, open-label, phase 1/2 study, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were started on pralsetinib dosed at 400 mg once daily. Overal… (full text at CIViC)

PMID 34118198 · Subbiah et al., 2021 · Open in CIViC

In this phase 1/2 study, 55 patients with RET-mutant medullary thyroid cancer who had previously received vandetanib and/or cabozantinib, 88 patients with the same disease who had not previously recei… (full text at CIViC)

PMID 32846061 · Wirth et al., 2020 · Open in CIViC

In this phase II trial, 404 patients with advanced NSCLC underwent ROS1 pre-screening, and 32 patients with ROS1 rearrangement confirmed with FISH were enrolled. All patients except two were crizotini… (full text at CIViC)

PMID 28520527 · Lim et al., 2017 · Open in CIViC

In the ongoing phase 1 study PROFILE 1001, NSCLC patients with ROS1 rearrangement confirmed by FISH or RT-PCR received crizotinib 250mg twice daily. Among 53 patients, the ORR was 72% (95% CI, 58% to … (full text at CIViC)

PMID 30980071 · Shaw et al., 2019 · Open in CIViC

In this study, the authors investigated the diagnostic role of TFCP2 fusions in spindle cell/sclerosing rhabdomyosarcoma (SC/S-RMS), a rare and aggressive subtype of rhabdomyosarcoma. While SC/S-RMS e… (full text at CIViC)

PMID 31383960 · Le Loarer et al., 2020 · Open in CIViC

This study investigated the role of TFCP2-related gene fusions in primary intraosseous rhabdomyosarcomas (PIOS), particularly within spindle cell and sclerosing rhabdomyosarcoma subtypes. The analysis… (full text at CIViC)

PMID 30720533 · Agaram et al., 2019 · Open in CIViC

This study screened 983 Renal Cell Carcinoma (RCC) cases and identified 65 tumors with morphologic features suspicious of RCC with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC). TFE3 immunohistoc… (full text at CIViC)

PMID 26169997 · He et al., 2015 · Open in CIViC

Argani. et al,. (2016) included a total of 60 cases with known TFE3 gene rearrangements in this study of Xp11 translocation positive neoplasms (47 RCC, 8 PEComa, and 5 melanotic renal cancers). The ag… (full text at CIViC)

PMID 26975036 · Argani et al., 2016 · Open in CIViC

Bakouny, et al. (2022) performed a comprehensive study of the molecular and clinical features of translocation renal cell carcinomas (tRCCs), defined as subtype of kidney cancer driven by MiT/TFE gene… (full text at CIViC)

PMID 34986355 · Bakouny et al., 2022 · Open in CIViC

Renal cell carcinomas (RCCs) with t(6;11)(p21;q12) are extremely rare and are characterized by a specific chromosome translocation involving the transcription factor EB (TFEB). Identification of eithe… (full text at CIViC)

PMID 22895266 · Rao et al., 2012 · Open in CIViC

In this 2022 study, the authors investigate the oncogenic role of the MYB::TYK2 fusion gene in high-risk B-lymphoblastic leukemia (HR B-ALL). TYK2 rearrangements are identified as recurrent events in … (full text at CIViC)

PMID 35022522 · Shirazi et al., 2022 · Open in CIViC

Expression of WDR12 was found to be significantly higher in tumour than normal tissue from TCGA LGG and GBM datasets. Kaplan-Meier analysis showed high WDR12 expression to be significantly associated … (full text at CIViC)

PMID 32180229 · Li et al., 2020 · Open in CIViC

This gene was identified as recurrently mutated in an analysis of 574 DLBCL exomes. Incidence is less than 3% in most cohorts so its relevance remains unclear.

PMID 29641966 · Schmitz et al., 2018 · Open in CIViC

Significant WEE1 protein overexpression was detected by IHC in VUMC-DIPG-1 tissue isolated from a patient's frontal lobe. Significant WEE1 protein levels were also found in E98-FM glioma cells. An i… (full text at CIViC)

PMID 23270927 · Caretti et al., 2013 · Open in CIViC

Two mouse xenograft models were used: one of tumor cells from a genetically engineered mouse with a BRAF V600E mutation, and the other using a patient's DIPG cells (SF8628). SF8628 was found to have … (full text at CIViC)

PMID 24305702 · Mueller et al., 2014 · Open in CIViC

The presence of the WEE1 polymorphism rs3910384 correlated with OS and PFS of NSCLC patients treated with platinum-based chemotherapy. Especially the combination of two DNA-damaging agents was associa… (full text at CIViC)

PMID 26057002 · Liu et al., 2015 · Open in CIViC

Described in recent genome-wide study of BL and DLBCL

PMID 36201743 · Thomas et al., 2023 · Open in CIViC

Expression of secreted factor Wnt-11 is increased in several types of cancer, including colorectal cancer, where it promotes cancer cell migration and invasion. Analysis of colorectal cancer gene expr… (full text at CIViC)

PMID 31261741 · Gorroño-Etxebarria et al., 2019 · Open in CIViC

In the AOM–DSS mouse colon tumor model (n = 8/group), aspirin (28 mg/kg/day) reduced tumor number and decreased epithelial proliferation (Ki67 and BrdU staining) and lowered circulating pro-inflammato… (full text at CIViC)

PMID 34033814 · Feng et al., 2021 · Open in CIViC

Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AM… (full text at CIViC)

PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC

No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML.

PMID 19221039 · Gaidzik et al., 2009 · Open in CIViC